• Kyorin Pharmaceutical posted Q1 net sales of JPY 29.65 billion, down 1.9% year-on-year.
• Operating profit plunged 59.3% to JPY 964 million, while profit attributable to owners of parent slid 60.8% to JPY 824 million.
• Full-year guidance under Japanese GAAP calls for net sales of JPY 121.8 billion, down 3.5%, with operating profit falling 43.9% to JPY 2 billion.
• The company forecasts profit attributable to owners of parent of JPY 1.5 billion, down 56.5%, with full-year EPS of JPY 26.11.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyorin Pharmaceutical Co. Ltd. published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein.